Bristol-Myers Squibb Company (BMY) 68.87 $BMY
Bristol-Myers' Opdivo Study Stopped Early, Meets Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 4:00PM CDT
Bristol-Myers Squibb (BMY) announced that the randomized phase III study, CheckMate -025, in patients with advanced or metastatic renal cell carcinoma (RCC) was stopped early.
EBIO: 2.95 (-0.04), SNSS: 3.45 (+0.05), AMAG: 72.59 (-1.83), BMY: 68.87 (-1.10)
Bristol-Myers Squibb Set to Possibly Rebound After Yesterday's Selloff of 1.57%
Comtex SmarTrend(R) - Tue Jul 21, 3:57PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $68.86 to a high of $70.20. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $68.89 on volume of 6.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 68.87 (-1.10)
After Yesterday's Decline of 1.57%, Bristol-Myers Squibb Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 21, 3:56PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $68.86 to a high of $70.20. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $68.89 on volume of 6.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 68.87 (-1.10)
Can Bristol-Myers (BMY) Keep its Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 3:20PM CDT
Bristol-Myers Squibb Company (BMY) is scheduled to report its second-quarter 2015 results on Apr 28, before the opening bell.
VRX: 240.59 (+0.71), ESRX: 93.42 (+1.53), MDCO: 33.85 (+0.13), BMY: 68.87 (-1.10)
Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development
Business Wire - Tue Jul 21, 1:00PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) today announced additional Phase IIa proof-of-concept data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1. The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral activity of BMS-955176 when administered with atazanavir (± ritonavir) and support further development of the second-generation HIV-1 maturation inhibitor.
BMY: 68.87 (-1.10)
Bristol-Myers says HIV drug gets FDA incentives
AP - Tue Jul 21, 12:15PM CDT
NEW YORK (AP) — Bristol-Myers said Tuesday that federal regulators will help speed up development for one of its experimental HIV drugs.
BMY: 68.87 (-1.10)
The rogues gallery of accounting scandals through the years
By The Associated Press - AP - Tue Jul 21, 11:28AM CDT
The resignation of nine Toshiba executives, including the CEO, for doctoring books places the company beside the growing rogues' gallery of corporate desperados. Here's a look at some of the most notorious.
RDS.B: 57.34 (+0.27), RDS.A: 57.03 (+0.35), AIG: 64.00 (-0.04), BMY: 68.87 (-1.10)
Global Fibrosis Therapeutics Pipeline Report 2015 - 32 Companies & 51 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjw3lt/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AiCuris GmbH & Co. KG - AnaMar AB - Arena Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - KineMed, Inc. - Lycera Corp. - MandalMed, Inc. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Pfizer Inc. - Promedior, Inc. - ProMetic Life Sciences Inc. - RuiYi Inc. - Scholar Rock, Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - Taisho Pharmaceutical Co., Ltd. - TRACON Pharmaceuticals, Inc. - UCB S.A. - Vericel Corporation - VivaCell Biotechnology Espana S.L. For more information visit http://www.researchandmarkets.com/research/rjw3lt/fibrosis
VCEL: 3.47 (-0.08), KNMD: (), PFE: 35.14 (-0.10), GALT: 2.67 (+0.03), GLYC: 7.52 (+0.10), BMY: 68.87 (-1.10), ICPT: 271.32 (-5.83), FGEN: 24.67 (-0.07), TCON: 13.13 (unch), ARNA: 4.30 (-0.05), XLRN: 30.79 (-1.79), FPRX: 24.89 (-0.29)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.34 (-0.03), ISIS: 56.18 (+0.50), GILD: 117.78 (-0.42), PFE: 35.14 (-0.10), SGMO: 9.71 (-0.25), BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), XLRN: 30.79 (-1.79)
Major Depressive Disorder Pipeline Review, H1 2015 - 37 Companies & 32 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6wpzn/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Alkermes Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics plc - Edgemont Pharmaceuticals, LLC - Eli Lilly and Company - Euthymics Bioscience, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. Drug Profiles - (aripiprazole sertraline) - (samidorphan buprenorphine hydrochloride) - amitifadine - AN-788 - aripiprazole - AV-101 - AVP-786 - basimglurant - brexpiprazole - bupropion hydrochloride ER - cariprazine - CERC-301 - desvenlafaxine succinate SR - EDG-005 - edivoxetine - esketamine hydrochloride - INASTR-001 - ITI-007 - lurasidone hydrochloride - LY-03005 - LY-2940094 - MIN-117 - miR-135 - MSI-195 - NLF-NEU - NRX-1074 - NSI-189 - onabotulinumtoxin A - PH-10 - rapastinel - RP-5063 - SEP-363856 For more information visit http://www.researchandmarkets.com/research/m6...depressive
JNJ: 100.34 (-0.03), ITCI: 28.95 (-1.15), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), ALKS: 68.51 (-1.64), CUR: 1.72 (-0.03)
Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx3h4b/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - Amphera BV - Applied Research using OMIC Sciences, S.L. - arGEN-X BV - ArQule, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - CanBas Co., Ltd. - Concordia Healthcare Corp. - CritiTech, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lx3h4b/malignant
ADRO: 28.50 (+0.80), ARQL: 1.84 (+0.01), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), EGRX: 87.74 (-2.83), BMY: 68.87 (-1.10), MRK: 58.67 (-0.33), AVEO: 1.68 (+0.06), CALA: 9.15 (+1.32), JUNO: 50.10 (-0.03), FPRX: 24.89 (-0.29), CXRX: 80.55 (+1.70)
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
Business Wire - Tue Jul 21, 8:00AM CDT
--FDA Breakthrough Designation recognizes the need for new therapies for heavily treatment-experienced HIV-1 patients and may expedite the development and review of BMS-663068
BMY: 68.87 (-1.10)
Potential Kidney Cancer Drugs Could Revolutionize Treatment
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 21, 7:05AM CDT
Source: Bristol-Myers Squibb. If treated early enough, kidney cancer patients have a five-year survival rate that is better than many other cancers. Unfortunately, though, treatment options are more limited, and survival rates less optimistic, for...
BMY: 68.87 (-1.10), EXEL: 6.05 (+0.17)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 35.14 (-0.10), ARQL: 1.84 (+0.01), SPPI: 7.27 (-0.14), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), MACK: 9.84 (-0.41), MRK: 58.67 (-0.33), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), DCTH: 0.49 (-0.03), NVS: 103.71 (-2.41), ARRY: 6.73 (-0.06), CELGZ: 2.19 (+0.01), CXRX: 80.55 (+1.70), EXEL: 6.05 (+0.17)
Bristol-Myers: kidney drug win
at Investor's Business Daily - Mon Jul 20, 5:41PM CDT
The big pharma said that its Opdivo scored another win Mon. as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. The trial compared Opdivo with everolimus, better known as Novartis' (NVS) Afinitor, in...
BMY: 68.87 (-1.10), EXEL: 6.05 (+0.17), NVS: 103.71 (-2.41)
European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer
Business Wire - Mon Jul 20, 11:07AM CDT
--Approval based on Checkmate -017, which showed nivolumab had a 41% reduction in the risk of death versus docetaxel, and demonstrated nearly doubled overall survival at one-year versus chemotherapy (42% vs. 24%); file also included data from CheckMate -063
BMY: 68.87 (-1.10)
Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer
at Investor's Business Daily - Mon Jul 20, 9:50AM CDT
Big pharma Bristol-Myers Squibb's (BMY) new drug Opdivo scored another win Monday, as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. Small biotech Exelixis (EXEL) also reported success in a...
BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Watch List for Drug Manufacturers - Major Equities -- Pfizer, Bristol-Myers Squibb, Eli Lilly, Kythera Biopharma, and Impax Laboratories
PR Newswire - Mon Jul 20, 8:25AM CDT
Equity Research Institute has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH), and Impax Laboratories Inc. (NASDAQ: IPXL). Free research report on Pfizer can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PFE On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
IPXL: 49.65 (+0.42), KYTH: 74.36 (-0.03), PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), BMY: 68.87 (-1.10)
CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early
Business Wire - Mon Jul 20, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) versus everolimus in previously-treated patients with advanced or metastatic renal cell carcinoma (RCC) was stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company looks forward to sharing these data with health authorities soon.
BMY: 68.87 (-1.10)
The Lowdown on This Week's Big Earnings
at The Street - Sun Jul 19, 7:14PM CDT
Futures are mixed as quarterly results begin to obscure Greece.
ODFL: 69.41 (+0.87), UTX: 102.71 (-7.77), TM: 134.56 (-0.98), LUV: 34.71 (+0.40), T: 34.57 (-0.33), V: 72.02 (-0.68), IBM: 163.07 (-10.15), CMG: 673.07 (-4.93), QCOM: 65.14 (+1.35), AAL: 40.90 (+0.35), CAT: 82.22 (-0.03), MSFT: 47.28 (+0.36), UNP: 98.82 (+0.51), TRV: 104.48 (+1.87), KO: 41.19 (-0.19), HAS: 80.42 (-2.73), AMZN: 488.00 (-0.10), AXP: 78.95 (-0.35), HAL: 41.86 (+1.14), LLY: 85.57 (-2.30), BMY: 68.87 (-1.10), BA: 145.00 (-1.72), UAL: 55.97 (+0.62), MS: 40.08 (+0.04), UA: 88.34 (-0.61), NTT: 37.24 (-0.20), TXN: 50.23 (+0.14), VZ: 46.97 (-1.13), SNDK: 55.48 (unch), BABA: 82.54 (-0.13)
Bristol-Myers' Opdivo Study Stopped Early, Meets Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 4:00PM CDT
Bristol-Myers Squibb (BMY) announced that the randomized phase III study, CheckMate -025, in patients with advanced or metastatic renal cell carcinoma (RCC) was stopped early.
EBIO: 2.95 (-0.04), SNSS: 3.45 (+0.05), AMAG: 72.59 (-1.83), BMY: 68.87 (-1.10)
Bristol-Myers Squibb Set to Possibly Rebound After Yesterday's Selloff of 1.57%
Comtex SmarTrend(R) - Tue Jul 21, 3:57PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $68.86 to a high of $70.20. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $68.89 on volume of 6.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 68.87 (-1.10)
After Yesterday's Decline of 1.57%, Bristol-Myers Squibb Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 21, 3:56PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $68.86 to a high of $70.20. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $68.89 on volume of 6.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 68.87 (-1.10)
Can Bristol-Myers (BMY) Keep its Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 3:20PM CDT
Bristol-Myers Squibb Company (BMY) is scheduled to report its second-quarter 2015 results on Apr 28, before the opening bell.
VRX: 240.59 (+0.71), ESRX: 93.42 (+1.53), MDCO: 33.85 (+0.13), BMY: 68.87 (-1.10)
Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development
Business Wire - Tue Jul 21, 1:00PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) today announced additional Phase IIa proof-of-concept data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1. The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral activity of BMS-955176 when administered with atazanavir (± ritonavir) and support further development of the second-generation HIV-1 maturation inhibitor.
BMY: 68.87 (-1.10)
Bristol-Myers says HIV drug gets FDA incentives
AP - Tue Jul 21, 12:15PM CDT
NEW YORK (AP) — Bristol-Myers said Tuesday that federal regulators will help speed up development for one of its experimental HIV drugs.
BMY: 68.87 (-1.10)
The rogues gallery of accounting scandals through the years
By The Associated Press - AP - Tue Jul 21, 11:28AM CDT
The resignation of nine Toshiba executives, including the CEO, for doctoring books places the company beside the growing rogues' gallery of corporate desperados. Here's a look at some of the most notorious.
RDS.B: 57.34 (+0.27), RDS.A: 57.03 (+0.35), AIG: 64.00 (-0.04), BMY: 68.87 (-1.10)
Global Fibrosis Therapeutics Pipeline Report 2015 - 32 Companies & 51 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjw3lt/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AiCuris GmbH & Co. KG - AnaMar AB - Arena Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - KineMed, Inc. - Lycera Corp. - MandalMed, Inc. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Pfizer Inc. - Promedior, Inc. - ProMetic Life Sciences Inc. - RuiYi Inc. - Scholar Rock, Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - Taisho Pharmaceutical Co., Ltd. - TRACON Pharmaceuticals, Inc. - UCB S.A. - Vericel Corporation - VivaCell Biotechnology Espana S.L. For more information visit http://www.researchandmarkets.com/research/rjw3lt/fibrosis
VCEL: 3.47 (-0.08), KNMD: (), PFE: 35.14 (-0.10), GALT: 2.67 (+0.03), GLYC: 7.52 (+0.10), BMY: 68.87 (-1.10), ICPT: 271.32 (-5.83), FGEN: 24.67 (-0.07), TCON: 13.13 (unch), ARNA: 4.30 (-0.05), XLRN: 30.79 (-1.79), FPRX: 24.89 (-0.29)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.34 (-0.03), ISIS: 56.18 (+0.50), GILD: 117.78 (-0.42), PFE: 35.14 (-0.10), SGMO: 9.71 (-0.25), BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), XLRN: 30.79 (-1.79)
Major Depressive Disorder Pipeline Review, H1 2015 - 37 Companies & 32 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6wpzn/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Alkermes Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics plc - Edgemont Pharmaceuticals, LLC - Eli Lilly and Company - Euthymics Bioscience, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. Drug Profiles - (aripiprazole sertraline) - (samidorphan buprenorphine hydrochloride) - amitifadine - AN-788 - aripiprazole - AV-101 - AVP-786 - basimglurant - brexpiprazole - bupropion hydrochloride ER - cariprazine - CERC-301 - desvenlafaxine succinate SR - EDG-005 - edivoxetine - esketamine hydrochloride - INASTR-001 - ITI-007 - lurasidone hydrochloride - LY-03005 - LY-2940094 - MIN-117 - miR-135 - MSI-195 - NLF-NEU - NRX-1074 - NSI-189 - onabotulinumtoxin A - PH-10 - rapastinel - RP-5063 - SEP-363856 For more information visit http://www.researchandmarkets.com/research/m6...depressive
JNJ: 100.34 (-0.03), ITCI: 28.95 (-1.15), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), ALKS: 68.51 (-1.64), CUR: 1.72 (-0.03)
Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx3h4b/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - Amphera BV - Applied Research using OMIC Sciences, S.L. - arGEN-X BV - ArQule, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - CanBas Co., Ltd. - Concordia Healthcare Corp. - CritiTech, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lx3h4b/malignant
ADRO: 28.50 (+0.80), ARQL: 1.84 (+0.01), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), EGRX: 87.74 (-2.83), BMY: 68.87 (-1.10), MRK: 58.67 (-0.33), AVEO: 1.68 (+0.06), CALA: 9.15 (+1.32), JUNO: 50.10 (-0.03), FPRX: 24.89 (-0.29), CXRX: 80.55 (+1.70)
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
Business Wire - Tue Jul 21, 8:00AM CDT
--FDA Breakthrough Designation recognizes the need for new therapies for heavily treatment-experienced HIV-1 patients and may expedite the development and review of BMS-663068
BMY: 68.87 (-1.10)
Potential Kidney Cancer Drugs Could Revolutionize Treatment
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 21, 7:05AM CDT
Source: Bristol-Myers Squibb. If treated early enough, kidney cancer patients have a five-year survival rate that is better than many other cancers. Unfortunately, though, treatment options are more limited, and survival rates less optimistic, for...
BMY: 68.87 (-1.10), EXEL: 6.05 (+0.17)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 35.14 (-0.10), ARQL: 1.84 (+0.01), SPPI: 7.27 (-0.14), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), MACK: 9.84 (-0.41), MRK: 58.67 (-0.33), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), DCTH: 0.49 (-0.03), NVS: 103.71 (-2.41), ARRY: 6.73 (-0.06), CELGZ: 2.19 (+0.01), CXRX: 80.55 (+1.70), EXEL: 6.05 (+0.17)
Bristol-Myers: kidney drug win
at Investor's Business Daily - Mon Jul 20, 5:41PM CDT
The big pharma said that its Opdivo scored another win Mon. as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. The trial compared Opdivo with everolimus, better known as Novartis' (NVS) Afinitor, in...
BMY: 68.87 (-1.10), EXEL: 6.05 (+0.17), NVS: 103.71 (-2.41)
European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer
Business Wire - Mon Jul 20, 11:07AM CDT
--Approval based on Checkmate -017, which showed nivolumab had a 41% reduction in the risk of death versus docetaxel, and demonstrated nearly doubled overall survival at one-year versus chemotherapy (42% vs. 24%); file also included data from CheckMate -063
BMY: 68.87 (-1.10)
Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer
at Investor's Business Daily - Mon Jul 20, 9:50AM CDT
Big pharma Bristol-Myers Squibb's (BMY) new drug Opdivo scored another win Monday, as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. Small biotech Exelixis (EXEL) also reported success in a...
BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), EXEL: 6.05 (+0.17)
Watch List for Drug Manufacturers - Major Equities -- Pfizer, Bristol-Myers Squibb, Eli Lilly, Kythera Biopharma, and Impax Laboratories
PR Newswire - Mon Jul 20, 8:25AM CDT
Equity Research Institute has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH), and Impax Laboratories Inc. (NASDAQ: IPXL). Free research report on Pfizer can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PFE On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
IPXL: 49.65 (+0.42), KYTH: 74.36 (-0.03), PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), BMY: 68.87 (-1.10)
CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early
Business Wire - Mon Jul 20, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) versus everolimus in previously-treated patients with advanced or metastatic renal cell carcinoma (RCC) was stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company looks forward to sharing these data with health authorities soon.
BMY: 68.87 (-1.10)
The Lowdown on This Week's Big Earnings
at The Street - Sun Jul 19, 7:14PM CDT
Futures are mixed as quarterly results begin to obscure Greece.
ODFL: 69.41 (+0.87), UTX: 102.71 (-7.77), TM: 134.56 (-0.98), LUV: 34.71 (+0.40), T: 34.57 (-0.33), V: 72.02 (-0.68), IBM: 163.07 (-10.15), CMG: 673.07 (-4.93), QCOM: 65.14 (+1.35), AAL: 40.90 (+0.35), CAT: 82.22 (-0.03), MSFT: 47.28 (+0.36), UNP: 98.82 (+0.51), TRV: 104.48 (+1.87), KO: 41.19 (-0.19), HAS: 80.42 (-2.73), AMZN: 488.00 (-0.10), AXP: 78.95 (-0.35), HAL: 41.86 (+1.14), LLY: 85.57 (-2.30), BMY: 68.87 (-1.10), BA: 145.00 (-1.72), UAL: 55.97 (+0.62), MS: 40.08 (+0.04), UA: 88.34 (-0.61), NTT: 37.24 (-0.20), TXN: 50.23 (+0.14), VZ: 46.97 (-1.13), SNDK: 55.48 (unch), BABA: 82.54 (-0.13)
